Pentolinium

Summary

Pentolinium (CHEMBL1271) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 240.43 Da · C15H32N2+2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1271
Name	Pentolinium
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5850
ChEBI	CHEBI:347401
Molecular formula	C15H32N2+2
Molecular weight	240.43
InChIKey	XSBSKEQEUFOSDD-UHFFFAOYSA-N

SMILES: C[N+]1(CCCC1)CCCCC[N+]2(CCCC2)C

IUPAC name: 1-methyl-1-[5-(1-methylpyrrolidin-1-ium-1-yl)pentyl]pyrrolidin-1-ium

ChEBI definition: A dication whose structure comprises a pentane backbone linking two 1-methylpyrrolidinium groups; a nicotinic antagonist used as a ganglionic blocking agent in hypertension.

Also known as: Pentolinium cation, Pentolinium ion, Pentolonium, Pentolinium, pentolinium, pentolonium, PENTOLINIUM

Parent form; salt/anhydrous children: CHEMBL118902, CHEMBL1318287, CHEMBL1356989

Patent coverage: 340 distinct patent families (1,093 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).